Induced pluripotent stem cell models for pharmacogenomics.

The Burridge lab works in the field of pharmacogenomics (precision medicine) using human induced pluripotent stems cell to study cardio-oncology and cardiovascular disease modeling. We also have projects related to large-scale differentiated cell production for regenerative medicine,  hiPSC models of cancer,  cultivated meat, and synthetic biology approaches to cell culture media development.

We specialize in large-scale hiPSC projects that required reprogramming, sequencing, editing, differentiating and phenotyping hundreds of hiPSC lines. 

We are responsible for a number of firsts including: the first directed cardiac differentiation protocol (Burridge et al., 2006), the first non-integrating reprogramming of blood to iPSC (Burridge et al., 2011), the first chemically defined differentiation protocol (Burridge et al., 2014), the first demonstration that doxorubicin-induced cardiotoxicity is a genomic disease (Burridge et al., 2016), the first cost-effective method of culturing iPSC (Kuo et al., 2020 and Lyra-Leite et al., 2023), the genomic basis of predisposition to doxorubicin-induced cardiotoxicity (Magdy et al., 2021 and 2022), and most recently the maturation of hiPSC-CMs (Fetterman et al., 2024).